ArticleCommunications medicine2025
A multimodal framework for comprehensive driver variant prediction in cancer.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer genomes contain many mutations, but only a subset drive tumor development. Accurately pinpointing these driver variants remains challenging. We aim to build an accurate and interpretable model by combining DNA sequence, protein 3D structure, and cancer omics data.
methodsWe present ModVAR, a multimodal model that integrates DNA sequences, predicted protein tertiary structures, and cancer omics data to classify driver variants. The approach uses pre-trained models (DNAbert2 and ESMFold) and a self-supervised strategy for cancer omics profiles. We evaluate performance on clinically and experimentally validated driver variants with standard classification metrics, examine therapeutic relevance through molecular docking, assess modeling of variants in intrinsically disordered protein regions, and analyze modality contributions.
resultsHere we show that ModVAR achieves strong accuracy across benchmarks for identifying validated driver variants. It prioritizes variants with potential therapeutic actionability supported by docking analyses, and the inclusion of structural predictions enables effective modeling of variants in intrinsically disordered regions. Interpretation indicates that the protein structure modality contributes most to predictions. At scale, the method produces 3,971,946 publicly available variant annotations.
conclusionsModVAR integrates sequence, structure, and cancer omics signals to aid driver-variant discovery. It provides robust performance across tasks, supports hypothesis generation and target discovery, and supplies a large-scale resource that advances cancer research and personalized therapy.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.